About ABK Biomedical
ABK Biomedical is a company based in Halifax (Canada) founded in 2012.. ABK Biomedical has raised $139.93 million across 7 funding rounds from investors including J P Morgan, Varian and Eight Roads Ventures. The company has 49 employees as of May 27, 2025. ABK Biomedical offers products and services including Eye90 microspheres and Easi-Vue embolic microspheres. ABK Biomedical operates in a competitive market with competitors including RefleXion, Alpha Tau Medical, Mevion Medical Systems, ZAP-X and Starget Pharma, among others.
- Headquarter Halifax, Canada
- Employees 49 as on 27 May, 2025
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Abk
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$139.93 M (USD)
in 7 rounds
-
Latest Funding Round
$35 M (USD), Series D
Oct 14, 2025
-
Investors
J P Morgan
& 6 more
-
Employee Count
49
as on May 27, 2025
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ABK Biomedical
ABK Biomedical offers a comprehensive portfolio of products and services, including Eye90 microspheres and Easi-Vue embolic microspheres. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Y90 radioembolization device for liver cancer treatment
Product for embolization of tumors and malformations
Unlock access to complete
Funding Insights of ABK Biomedical
ABK Biomedical has successfully raised a total of $139.93M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $35 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series D — $35.0M
-
First Round
First Round
(24 Oct 2012)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Series D - ABK Biomedical | Valuation | J P Morgan | |
| Apr, 2025 | Amount | Series C - ABK Biomedical | Valuation |
investors |
|
| Dec, 2022 | Amount | Series C - ABK Biomedical | Valuation | Sante |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ABK Biomedical
ABK Biomedical has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include J P Morgan, Varian and Eight Roads Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Santé is engaged in healthcare and technology investment management.
|
Founded Year | Domain | Location | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Founded Year | Domain | Location | |
|
Venture capital investment and global platform support for startups.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ABK Biomedical
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ABK Biomedical
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Abk Biomedical Comparisons
Competitors of ABK Biomedical
ABK Biomedical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as RefleXion, Alpha Tau Medical, Mevion Medical Systems, ZAP-X and Starget Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biology-guided radiotherapy systems are provided for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Radiotherapy technique for solid tumors is developed using alpha-emitting seeds.
|
|
| domain | founded_year | HQ Location |
Proton therapy systems are supplied for cancer radiation treatment.
|
|
| domain | founded_year | HQ Location |
Developer of gyroscopic radiosurgery platform
|
|
| domain | founded_year | HQ Location |
Targeted radiopharmaceuticals are developed for solid tumor treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Abk Biomedical
Frequently Asked Questions about ABK Biomedical
When was ABK Biomedical founded?
ABK Biomedical was founded in 2012.
Where is ABK Biomedical located?
ABK Biomedical is headquartered in Halifax, Canada. It is registered at Halifax, Nova Scotia, Canada.
Is ABK Biomedical a funded company?
ABK Biomedical is a funded company, having raised a total of $139.93M across 7 funding rounds to date. The company's 1st funding round was a Series C of $30M, raised on Oct 24, 2012.
How many employees does ABK Biomedical have?
As of May 27, 2025, the latest employee count at ABK Biomedical is 49.
What does ABK Biomedical do?
ABK Biomedical was founded in 2012 in Halifax, Canada, within the biomedical sector. Embolic medical devices are developed for treating benign and malignant hypervascular tumors. Eye90 microspheres, designed for Y-90 radioembolization, are used in liver tumor therapy and enable CT imaging for dosimetry. Easi-Vue embolic microspheres are provided for bland embolization, allowing visualization at target sites. Operations focus on device innovation for oncology applications.
Who are the top competitors of ABK Biomedical?
ABK Biomedical's top competitors include RefleXion, Alpha Tau Medical and Starget Pharma.
What products or services does ABK Biomedical offer?
ABK Biomedical offers Eye90 microspheres and Easi-Vue embolic microspheres.
Who are ABK Biomedical's investors?
ABK Biomedical has 7 investors. Key investors include J P Morgan, Varian, Eight Roads Ventures, Santé, and F-Prime Capital.